The groundbreaking success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but placing funds in companies strongly reliant on unbranded versions presents a uncertain picture. While early returns were significant, the cessation of patents and the emergence of less expensive alternatives have diminished sales. Thus, a thorough a